Advice
In the absence of a submission from the holder of the marketing authorisation
zoledronic acid 5mg (Aclasta®) is not recommended for use within NHSScotland for the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice53KB (PDF)
Medicine details
- Medicine name:
- zoledronic acid (Aclasta)
- SMC ID:
- 535/08
- Indication:
- Treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 January 2009